Dr. Robert Buchanan joined Ventac Partners as a Partner in April of 2007. He has over 20 years of experience in senior legal and company management roles in the United States and Europe. He currently serves as General Counsel for Avexxin AS, a clinical stage biopharmaceutical company developing new anti-inflammatory agents. Other past executive level positions include Chief Executive Officer at Regenesance B.V, a company Dr. Buchanan co-founded ( with Ventac Partners) and where he helped raise over USD $7M in upfront and milestone driven funding.
Prior to joining Avexxin AS as General Counsel, Dr. Buchanan was Associate General Counsel at Biogen (NASDAQ:BIIB) where responsibilities included oversight of the company’s early stage haemophilia patent portfolio and strengthening its R&D collaboration pipeline in gene therapy and gene editing. He was lead or co-lead IP counsel for a broad range of transactions in which total upfront and future milestone payments exceeded USD $1.25B.
Earlier in his career, Dr. Buchanan was co-chair of the Life Sciences Practice Group of Edwards Angell Palmer & Dodge in Boston (now Locke Lord) where he managed an international patent portfolio of start-up, mid-size, blue chip and academic clients. In that role, he was frequently invited to speak on IP developments throughout the US and Europe.
Dr. Buchanan is a board member of Ahram Biosystems, Inc. (PCR technologies) and, along with Ventac Partners, is a co-founder of Idogen AB: a company listed on the Swedish stock exchange in (IDOGEN:ST).
Dr. Buchanan received a BS from the University of Massachusetts, Amherst (Biochemistry, cum laude), a PhD from the University of California, Los Angeles (Biochemistry), and a JD in law from Suffolk University, Boston. He is also a past Biology Fellow with the California Institute of Technology, Pasadena. He is a registered patent attorney with the United States Patent & Trademark Office and is licensed to practice law before state courts in Massachusetts and the US District Court of Massachusetts.